The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma

Neuro-Oncology

Volumn 14, Issue 5, 2012, Pages 596-612

  Andolfo, Immacolata ^a,b   Liguori, Lucia ^a   De Antonellis, Pasqualino ^a   Cusanelli, Emilio ^a   Marinaro, Federica ^a   Pistollato, Francesca ^a,d   Garzia, Livia ^a   De Vita, Gennaro ^a   Petrosino, Giuseppe ^a   Accordi, Benedetta ^d   Migliorati, Roberta ^c   Basso, Giuseppe ^d   Iolascon, Achille ^a,b   Cinalli, Giuseppe ^c   Zollo, Massimo ^a,c  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

CD15; Epigenetic mechanism; Hes1; Medulloblastoma; MiR 199b 5p

Indexed keywords

CD133 ANTIGEN; CD15 ANTIGEN; MICRORNA; MICRORNA 199B 5P; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CHILD; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; INFANT; MALE; MEDULLOBLASTOMA; NEGATIVE FEEDBACK; PRESCHOOL CHILD; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; TUMOR CELL LINE;

ANTIGENS, CD15; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CEREBELLAR NEOPLASMS; CHILD, PRESCHOOL; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; DNA METHYLATION; EPIGENOMICS; FEMALE; FLOW CYTOMETRY; FUCOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; INFANT; KIDNEY; MALE; MEDULLOBLASTOMA; MICRORNAS; PRIMARY CELL CULTURE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84860378895     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos002     Document Type: Article

References (64)

1. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol. 2002;28(4): 257-282.
2. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22(6):984-993.
3. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol. 2003;7(2):53-66.
4. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol. 2008;3:341-365.
5. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10(5):319-331.
6. Eberhart CG. In search of the medulloblast: neural stem cells and embryonal brain tumors. Neurosurg Clin N Am. 2007;18(1):59-69, viii-ix.
7. Jenkins D. Hedgehog signalling: emerging evidence for non-canonical pathways. Cellular Signalling. 2009;21(7):1023-1034.
8. Lauth M, Toftgard R. Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle (Georgetown, Tex.). 2007;6(20):2458-2463.
9. Morton JP, Lewis BC. Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle (Georgetown, Tex.). 2007;6(13):1553-1557.
10. Fan X, Mikolaenko I, Elhassan I, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res. 2004;64(21): 7787-7793.
11. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004;64(21):7794-7800.
12. Ingram WJ, McCue KI, Tran TH, Hallahan AR, Wainwright BJ. Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. Oncogene. 2008;27(10):1489-1500.
13. Schreck KC, Taylor P, Marchionni L, et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res. 2010;16(24):6060-6070.
14. Fouladi M, Stewart CF, Olson J, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 2011;29(26):3529-3534.
15. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;66(15):7445-7452.
16. Hatton BA, Villavicencio EH, Pritchard J, et al. Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene. 2010;29(26):3865-3872.
17. Julian E, Dave RK, Robson JP, Hallahan AR, Wainwright BJ. Canonical Notch signaling is not required for the growth of Hedgehog pathway-induced medulloblastoma. Oncogene. 2010;29(24): 3465-3476.
18. Ferretti E, De Smaele E, Miele E, et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008;27(19):2616-2627.
19. Ferretti E, De Smaele E, Po A, et al. MicroRNA profiling in human medulloblastoma. Int J Cancer. 2009;124(3):568-577.
20. Lu Y, Ryan SL, Elliott DJ, et al. Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One. 2009;4(7):e6159.
21. Northcott PA, Fernandez LA, Hagan JP, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 2009;69(8):3249-3255.
22. Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008;90(1):1-7.
23. Turner JD, Williamson R, Almefty KK, et al. The many roles of microRNAs in brain tumor biology. Neurosurg Focus. 2010;28(1):E3.
24. Uziel T, Karginov FV, Xie S, et al. The miR-17-92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci USA. 2009;106(8):2812-2817.
25. Garzia L, Andolfo I, Cusanelli E, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One. 2009;4(3):e4998.
26. Fruhwald MC, O'Dorisio MS, Dai Z, et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas-implications for tumor biology and potential clinical utility. Oncogene. 2001;20(36):5033-5042.
27. Lindsey JC, Anderton JA, Lusher ME, Clifford SC. Epigenetic events in medulloblastoma development. Neurosurg Focus. 2005;19(5):E10.
28. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet. 2009;41(4):465-472.
29. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41(2):178-186.
30. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
31. Davalos V, Esteller M. MicroRNAs and cancer epigenetics: a macrorevolution. Curr Opin Oncol. 2010;22(1):35-45.
32. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009;60:167-179.
33. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10(6):389-402.
34. Waldman SA, Terzic A. A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer. FEBS J. 2009;276(8):2157- 2164.
35. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell. 2007;26(5):753-767.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
37. Panchision DM, Chen HL, Pistollato F, Papini D, Ni HT, Hawley TS. Optimized flow cytometric analysis of central nervous system tissue reveals novel functional relationships among cells expressing CD133, CD15, and CD24. Stem Cells. 2007;25(6):1560-1570.
38. Toyota M, Suzuki H, Sasaki Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68(11):4123-4132.
39. Petricoin EF, 3rd, Bichsel VE, Calvert VS, et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005;23(15):3614-3621.
40. Petricoin EF, 3rd, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007;67(7):3431-3440.
41. Wulfkuhle JD, Aquino JA, Calvert VS, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics. 2003;3(11):2085-2090.
42. Espina V, Mehta AI, Winters ME, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics. 2003;3(11):2091-2100.
43. Clayton EL, Sue N, Smillie KJ, et al. Dynamin I phosphorylation by GSK3 controls activity-dependent bulk endocytosis of synaptic vesicles. Nature Neuroscience. 2010;13(7):845-851.
44. Abderrahmani A, Niederhauser G, Lenain V, Regazzi R, Waeber G. The hairy and enhancer of split 1 is a negative regulator of the repressor element silencer transcription factor. FEBS Lett. 2005;579(27): 6199-6204.
45. Ward RJ, Lee L, Graham K, et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res. 2009;69(11):4682-4690.
46. Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell. 2009;15(2):135-147.
47. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10): 1278-1284.
48. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009;27(10):1627-1636.
49. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer. 2001;85(5):705-712.
50. Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol. 2007;4(5):295-304.
51. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol. 2004;22(6):994-998.
52. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63(5):441-449.
53. Rutkowski S, von Bueren A, von Hoff K, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res. 2007;13(9):2651-2657.
54. Bennani-Baiti IM, Aryee DN, Ban J, et al. Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma. J Pathol. 2011;225(3):353-363.
55. Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle. 2007;6(12): 1455-1459.
56. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatinmodifying drugs in human cancer cells. Cancer Cell. 2006;9(6):435-443.
57. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007;67(4):1424-1429.
58. Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 2007;67(4):1419-1423.
59. Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008;27(50):6473-6488.
60. Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res. 2006;12(10):3019-3027.
61. Yuan L, Santi M, Rushing EJ, Cornelison R, MacDonald TJ. ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration. Clinical & Experimental Metastasis. 2010;27(7):481-491.
62. Abouantoun TJ, MacDonald TJ. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Molecular Cancer Therapeutics. 2009;8(5):1137-1147.
63. da Costa Martins PA, Salic K, Gladka MM, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nature Cell Biology. 2010;12(12):1220-1227.
64. Wang C, Song B, Song W, et al. Underexpressed microRNA-199b-5p targets Hypoxia-Inducible Factor-1alpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. Journal of Gastroenterology and Hepatology. 2011;26(11):1630-1637.